Actualités DICE Therapeutics Inc - DICE | Actions NASDAQ

Votre Hub pour des idées et discussions en direct en temps réel

Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

DICE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

SOUTH SAN FRANCISCO, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE...

Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr)

Table of Contents As filed with the Securities and Exchange Commission on March 15, 2023...

Securities Registration: Employee Benefit Plan (s-8)

As filed with the Securities and Exchange Commission on March 15, 2023 Registration No. 333- UNITED STATES...

Annual Report (10-k)

0001645569falseFY0001645569us-gaap:FairValueMeasurementsRecurringMember2022-12-310001645569dice:TermLoanMember...

DICE Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

IND application for DICE’s lead oral IL-17 antagonist, DC-806, cleared by FDA; global Phase 2b clinical trial...

DICE Therapeutics Announces Late-Breaking Presentation at the 2023 American Academy of Dermatology (AAD) Annual Meeting

SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a...

Statement of Ownership (sc 13g)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange...

Statement of Ownership (sc 13g)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the...

Statement of Ownership (sc 13g)

us23345j1043_021323.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the...

Current Report Filing (8-k)

0001645569false00016455692023-02-072023-02-07 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 FORM 8-K...

Amended Statement of Ownership (sc 13g/a)

SCHEDULE 13G Amendment No.1 DICE THERAPEUTICS INC COMMON STOCK Cusip #23345J104 Check the appropriate box to...

DICE Therapeutics to Participate at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

DICE Therapeutics Inc (DICE)

Votre Hub pour des idées et discussions en direct en temps réel

DICE Actualités

Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

DICE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr)

Securities Registration: Employee Benefit Plan (s-8)

Annual Report (10-k)

DICE Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

DICE Therapeutics Announces Late-Breaking Presentation at the 2023 American Academy of Dermatology (AAD) Annual Meeting

Statement of Ownership (sc 13g)

Statement of Ownership (sc 13g)

Statement of Ownership (sc 13g)

Current Report Filing (8-k)

Amended Statement of Ownership (sc 13g/a)

DICE Therapeutics to Participate at Upcoming Investor Conferences

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

DICE Therapeutics Inc (DICE) Actualités

DICE Therapeutics Inc (DICE)

Votre Hub pour des idées et discussions en direct en temps réel

DICE Actualités

Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

DICE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr)

Securities Registration: Employee Benefit Plan (s-8)

Annual Report (10-k)

DICE Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

DICE Therapeutics Announces Late-Breaking Presentation at the 2023 American Academy of Dermatology (AAD) Annual Meeting

Statement of Ownership (sc 13g)

Statement of Ownership (sc 13g)

Statement of Ownership (sc 13g)

Current Report Filing (8-k)

Amended Statement of Ownership (sc 13g/a)

DICE Therapeutics to Participate at Upcoming Investor Conferences

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application